Impaired NK cell recognition of vemurafenib-treated melanoma cells is overcome by simultaneous application of histone deacetylase inhibitors

Therapy of metastatic melanoma advanced recently with the clinical implementation of signalling pathway inhibitors, such as vemurafenib, specifically targeting mutant BRAF(V600E). In general, patients experience remarkable clinical responses under BRAF inhibitor (BRAFi) treatment but eventually prog...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncoimmunology
Main Authors: López-Cobo, Sheila, Pieper, Natalia, Campos-Silva, Carmen, García-Cuesta, Eva M., Reyburn, Hugh T., Paschen, Annette, Valés-Gómez, Mar
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2017
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5749663/
https://ncbi.nlm.nih.gov/pubmed/29308322
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2017.1392426
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados